Clinical Trials

BreastGastrointestinalGynecologicThoracic

264 enrolled 32 charts

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03820141 2026-04-20

DTP

51 enrolled 12 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT04176848 2026-02-18

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

15 enrolled 7 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04556773 2025-12-17

DB-08

138 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1 Active not recruiting

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

Phase 1 Active not recruiting

22 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05795101 2025-09-19

TRUDI

63 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

37 enrolled

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Breast Neoplasms

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

54 enrolled

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

172 enrolled

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

126 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03875573 2024-12-20

Neo-CheckRay

147 enrolled

Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

129 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

57 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06508216 2024-07-22

COMPASS-TNBC

Phase 1/2 Recruiting

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05215106 2024-07-08

POP-DURVA

200 enrolled

Cerebral Palsy, Triple Negative Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

42 enrolled

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

16 enrolled 8 charts

Anatomic Stage II Breast Cancer AJCC v8

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Phase 1 Terminated

18 enrolled 9 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Triple Negative Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02527434 2023-11-15

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2 Completed

64 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1 Completed

15 enrolled